Abstracts tagged "Clinical research"

Abstract Number: 471 • 2018 ACR/ARHP Annual Meeting
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
Joyce C. Chang^1,2, Brian R. White³, Matthew D. Elias³, Rui Xiao⁴, Andrea M. Knight^5,6,7, Pamela F. Weiss^8,9,10 and Laura M. Mercer-Rosa^3,7, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸Center for Clinical Epidemiology and Biostastistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (pSLE) are poorly understood, and the role of screening echocardiography remains unclear.…
Abstract Number: 13L • 2017 ACR/ARHP Annual Meeting
Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial
Dawn McGuire¹, Nancy E Lane², Neil Segal³, Samy Metyas⁴, Hans Richard Barthel⁵, Meghan Miller¹, David Rosen¹ and Yoshi Kumagai¹, ¹OrthoTrophix, Inc, Oakland, CA, ²UC Davis Medical Center, Sacramento, CA, ³University of Kansas, Shawnee, KS, ⁴Medvin Clinical Research, Covina, CA, ⁵Barthel Clinic, Santa Barbara, CA

Background/Purpose: The current Phase 2 study was designed to evaluate safety, tolerability and preliminary efficacy of TPX-100 by IA administration in subjects with mild to…
Abstract Number: 15L • 2017 ACR/ARHP Annual Meeting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Sukirti Bagal, Catherine Munera, Patricia Brady and Joseph Stauffer, Cara Therapeutics, Stamford, CT

Background/Purpose: CR845 is a selective kappa opioid receptor agonist with a peripheral mechanism of action. Here we report preliminary results from a Phase 2b study…
Abstract Number: 544 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
Spencer Danto¹, Negin Shojaee¹, Cheryl Li¹, Steven A. Gilbert², Ravi Shankar Singh¹, Zorayr Manukyan¹ and Iain Kilty¹, ¹Worldwide Research and Development, Pfizer, Inc., Cambridge, MA, ²Pfizer, Inc., Cambridge, MA
Background/Purpose: IRAK‑4 is a key node in innate immune signaling and is activated by the interleukin (IL)‑1 family receptors (IL‑1R, IL‑18R, and IL‑33R), in addition…
Abstract Number: 583 • 2017 ACR/ARHP Annual Meeting
Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis
Mark Hwang^1,2,3, Michael Weisman⁴, MinJae Lee⁵, Lianne S. Gensler⁶, Matt Brown⁷, Amirali Tahanan⁵, Laura A. Diekman⁸, Thomas Learch⁹, Seth Eisen¹⁰, Mohammad H. Rahbar⁵, Michael Ward¹¹ and John D. Reveille¹², ¹Medicine, University of Texas-McGovern Medical School, Houston, TX, ²Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Saint Louis, MO, ³Washington University at Saint Louis School of Medicine, Saint Louis, MO, ⁴Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ⁵Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine/Rheumatology, UCSF, San Francisco, CA, ⁷Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁸Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁹Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Washington University at Saint Louis School of Medicine, St Louis, MO, ¹¹NIH/NIAMS, Bethesda, MD, ¹²University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Metrology indices aimed as assessing spinal mobility in ankylosing spondylitis (AS) patients are used in clinical trials and clinical practice to assess disease severity…
Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Pernille Juhl¹, Mette Mogensen², Line Iversen², Tonny Karlsmark², Morten Karsdal³, Anne-C. Bay-Jensen⁴ and Anne Sofie Siebuhr⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…
Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting
48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
David Wofsy¹, David A. Isenberg², Frédéric A. Houssiau³, Mary Anne Dooley⁴, Neil Solomons⁵ and Simrat Randhawa⁶, ¹Rheumatology, UCSF, San Francisco, CA, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁴UNC Kidney Centre, Chapel Hill, NC, ⁵Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁶Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
Abstract Number: 1147 • 2017 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome or Acquired Hemophagocytic Lymphohistiocytosis in Adults: Demographics, Clinical Characteristics, and Survivorship in an American Academic Medical Center
Seema Malkana¹ and Irene Tan², ¹Internal Medicine, Temple University Hospital, Philadelphia, PA, ²Section of Rheumatology, Temple University Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Macrophage Activation Syndrome, also known as acquired Hemophagocytic Lymphohistiocytosis in adults, is an immune-mediated systemic inflammatory state. It is associated with multisystem organ failure…
Abstract Number: 1661 • 2017 ACR/ARHP Annual Meeting
STAT4 Regulates Pathogenic IL-21 and IFN-γ in Tfh Cells in Murine and Human Lupus
Fotios Koumpouras¹, XueMei Dong², Jason Weinstein² and Joseph E. Craft³, ¹Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ²Rheumatology, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: Follicular helper T cells (Tfh) cells regulate the germinal center (GC) response by delivery of contact-dependent interactions and cytokines including IL-4, IFN-γ and IL-21.…
Abstract Number: 1780 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Patients with Granulomatosis with Polyangiitis Requiring Hospitalization- a 10 Year Nationwide Analysis
Yumeng Wen¹, Yiming Luo¹ and Changchuan Jiang², ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Medicine, Mount Sinai St. Luke's West Hospitals. Icahn School of Medicine at Mount Sinai., New York, NY
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a form of systemic vasculitis with necrotizing granulomatous inflammation commonly involving upper and lower respiratory tracts, necrotizing glomerulonephritis and…
Abstract Number: 1854 • 2017 ACR/ARHP Annual Meeting
Identifying Vulnerable Patient Populations Based on Age and Physical Function on Clinical Outcomes Following Total Knee Arthroplasty
Jesse Christensen¹, Andrew Kittelson², Brian Loyd³, Jackie Del Giorno⁴, Brian Burnikel⁵ and Jennifer Stevens-Lapsley⁶, ¹University of Utah, SLC, UT, ²Rehabilitation Science PhD Program, University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴ATI Physical Therapy, Greenville, SC, ⁵Steadman Hawkins Clinic of the Carolinas, Greenville Health Systems, Greenville, SC, ⁶Universtiy of Colorado, Anschutz Medical Campus, Aurora, CO
Background/Purpose: : Total knee arthroplasty (TKA) has historically been viewed as a surgical procedure of last resort for older adults suffering with chronic arthritis. However,…
Abstract Number: 2167 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Valérie Leclair, Maryam Dastmalchi, Angeles Shunashy Galindo-Feria and Ingrid E. Lundberg, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rituximab (RTX) in idiopathic inflammatory myopathies (IIM) failed to show efficacy in the placebo-controlled Rituximab in Myositis (RIM) trial. However, post hoc analyses indicated…
Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Hermine I. Brunner¹, N Ruperto², G Vega-Cornejo³, A Berman⁴, Inmaculada Calvo⁵, R Cuttica⁶, F Ávila-Zapata⁷, Michael Henrickson¹, DJ Kingsbury⁸, D Viola⁹, V Keltsev¹⁰, K Minden¹¹, John F. Bohnsack¹², X Li¹³, M Nys¹⁴, R Wong¹³, S Banerjee¹³, Daniel J Lovell¹ and Alberto Martini¹⁵, ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁷Star Medica Hospital, Yucatán, Mexico, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹CAICI Institute, Rosario City, Santa Fe State, Argentina, ¹⁰GBUZ Samara region "Togliatti City Clinical Hospital No.5" Rheumatology Department, Togliatti, Russian Federation, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²University of Utah School of Medicine, Salt Lake City, UT, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…
Abstract Number: 3136 • 2016 ACR/ARHP Annual Meeting
Impact of Novel Smartphone Application on Pain and Mobility in Osteoarthritis Patients Treated with Hylan G-F 20
Nebojsa Skrepnik¹, Andrew Spitzer², Roy Altman³, John A. Hoekstra⁴, John Stewart⁵ and Richard Toselli⁶, ¹Tucson Orthopaedic Institute, Tucson, AZ, ²Cedars-Sinai Orthopedic Center, Los Angeles, CA, ³UCLA Medical Center, Los Angeles, CA, ⁴National Clinical Research–Richmond, Richmond, VA, ⁵Sanofi, Laval, QC, Canada, ⁶Sanofi, Cambridge, MA
Background/Purpose: Methods: In this study, both groups were treated with hylan G-F 20 and showed significantly increased mobility and reduced pain, however, patients using the…
Abstract Number: 242 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Features of IgG4-Related Retroperitoneal Fibrosis/Periarteritis in Japan: Retrospective Multicenter Study of 99 Cases
Ichiro Mizushima¹, Satomi Kasashima², Motohisa Yamamoto³, Takako Saeki⁴, Kazunori Yamada⁵, Dai Inoue⁶, Fuminori Kasashima⁷, Yasushi Matsumoto⁷, Eisuke Amiya⁸, Kenji Notohara⁹, Yasuharu Sato¹⁰, Yoh Zen¹¹, Shigeyuki Kawa¹², Mitsuhiro Kawano¹ and Nobukazu Ishizaka¹³, ¹Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ²Department of Clinical Laboratory and Pathology, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan, ³First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁵Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁶Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, ⁷Department of Cardiovascular Surgery, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan, ⁸Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁹Department of Pathology, Kurashiki Central Hospital, Kurashiki, Japan, ¹⁰Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan, ¹¹Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto, Japan, ¹³Department of Cardiology, Osaka Medical College, Osaka, Japan
<span">Background/Purpose: IgG4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disorder that can affect many organs. It frequently causes retroperitoneal/periarterial lesions, which are referred to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.